GlassScriptPhysician profile
William R Sonnenberg
NPI 1932173366
$13,942.94
in general payments reported to CMS, 2019-2025
32 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $7,735 · 2021: $1,457 · 2022: $641 · 2023: $696 · 2024: $545 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,006.87 | 2019-2020 | |
| Glaxosmithkline, LLC. | $1,059.50 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $825.06 | 2019-2022 | |
| Abbvie INC. | $646.20 | 2021-2022 | |
| Novo Nordisk INC | $521.45 | 2019-2022 | |
| Lilly USA, LLC | $505.23 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $458.96 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Indivior INC. | $217.48 | 2022-2024 | Sublocade |
| Novartis Pharmaceuticals Corporation | $181.14 | 2020-2024 | Leqvio |
| Otsuka America Pharmaceutical, INC. | $180.30 | 2023-2025 | Rexulti |
| Ferring Pharmaceuticals INC. | $167.73 | 2019-2020 | |
| Amgen INC. | $156.68 | 2020-2021 | |
| Abbott Laboratories | $149.91 | 2021 | |
| Sanofi-Aventis U.S. LLC | $145.70 | 2019-2020 | |
| Pfizer INC. | $115.11 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.75 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $88.63 | 2019-2025 | Austedo Xr |
| Verona Pharma, INC. | $51.09 | 2025 | Ohtuvayre |
| Lundbeck LLC | $50.55 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $41.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.45 | 2022 | |
| Neurocrine Biosciences, INC. | $37.23 | 2023-2024 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $37.10 | 2024 | Gvoke Hypopen |
| Nabriva Therapeutics, Plc | $32.41 | 2021 | |
| Alkermes, INC. | $29.12 | 2023 | Vivitrol |
| Esperion Therapeutics, INC. | $18.62 | 2025 | Nexletol |
| Axsome Therapeutics, INC. | $18.59 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $16.75 | 2023 | Gemtesa |
| Exact Sciences Corporation | $14.17 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $14.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.93 | 2020 | |
| Athena Bioscience, LLC | $11.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sonnenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.